RxDoctor Payments Data

Samer Shuaib, MD

Interventional Cardiology · Las Vegas, NVNPI 1720294440

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,893 of the $5,759 with a category attached, or 67.6%. 13 manufacturers reported payments, led by Medtronic at 46.2% of the total. 2025 is the largest year on record at $3,714, 3.0 times the $1,247 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in NV, where the typical reported total is $9,708.

$5,759in general payments, 2019–2025

Across 47 payments — averaging $122.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$2K
  • Cardiovascular Systems Inc.$661
  • Inari Medical, Inc.$163
  • Bard Peripheral Vascular, Inc.$143
  • Novo Nordisk$135
  • plus $270 from 7 others

What the payments were for

  • Travel & lodging$3,89368%
  • Food & beverage$1,84932%
  • Education$170%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,759 in reported general payments places this provider in the 25th percentile of 62 interventional cardiology providers in Nevada.

See all interventional cardiology providers in Nevada

Medicare billing

Part B allowed, 2024
$38,778
Medicare patients
306
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Isosorbide Mononitrate ErIsosorbide Mononitrate12$44

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →